Piper Sandler Initiates Coverage On CareDx with Overweight Rating, Announces Price Target of $100
Favorable Medicare Coverage Ruling Drives CareDx’s (CDNA) Q3 Performance
Should Earnings Upgrade Require Action From CareDx Stock Investors?
CareDx (NASDAQ:CDNA) Stands Out for High Growth and Improving Fundamentals
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know
CareDx, Inc. 2026 Q3 - Results - Earnings Call Presentation
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
CareDx (NASDAQ:CDNA): A Case for Affordable Growth
CareDx Announces Third KOAR Analysis Published in Transplantation
CareDx (CDNA) Stock Still Looks Reasonable Following Its Huge 3 Year Run
CareDx (CDNA) Q3 2026 Earnings Call Transcript
CareDx, Inc Q3 2026 Earnings Call Summary
CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript
BTIG Maintains Buy on CareDx, Raises Price Target to $92
What CareDx (CDNA) Said on Its Q3 Earnings Call
CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates
CareDx: Q3 Earnings Snapshot
CareDx Announces Third Quarter 2026 Financial Results
CareDx Raises FY2026 Sales Guidance from $490.000M-$500.000M to $520.000M-$530.000M vs $489.692M Est
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.